Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.45 |
| ▸ | RXRB | P28702 | 1/20 | 0.45 |
| ▸ | RXRG | P48443 | 1/20 | 0.45 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3726426 | 0.85 | PTGER1 (0.54) | ALDH1A1HTTSMN1; SMN2RXRARXRB | |
| SCHEMBL30955958 | 0.85 | PTGER1 (0.54) | ALDH1A1HTTSMN1; SMN2RXRARXRB | |
| SCHEMBL2146575 | 0.83 | CTSS (0.49) | NPSR1ALDH1A1HTTSMN1; SMN2CTSS | |
| SCHEMBL15600393 | 0.80 | CCR5 (0.51) | RXRARXRBRXRGS1PR4PTGER1 | |
| SCHEMBL30792394 | 0.78 | USP28 (0.55) | RXRARXRBRXRGS1PR4PTGER1 | |
| SCHEMBL13642078 | 0.77 | ALDH1A1 (0.53) | CYP3A4CYP1A2GLACYP2D6CYP2C9 | |
| SCHEMBL841828 | 0.77 | AAK1 (0.46) | CYP3A4CTSSRXRARXRBRXRG | |
| SCHEMBL842071 | 0.77 | RXRA (0.55) | CTSSRXRARXRBRXRGAR | |
| SCHEMBL320787 | 0.76 | HTT (0.52) | CYP3A4CYP1A2GLACYP2D6CYP2C9 | |
| SCHEMBL8236376 | 0.74 | S1PR4 (0.50) | CYP1A2CYP2C9CYP2C19ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115126-B2 | 1H-[1,2,3]triazolo[4,5-c]pyridine-4-carbonitrile derivatives | MERCK SHARP & DOHME B.V. (NL) | 2015-08-25 | — | — | US | disclosed |
| US-9115126-B2 | 1H-[1,2,3]triazolo[4,5-c]pyridine-4-carbonitrile derivatives | MERCK SHARP & DOHME B.V. (NL) | 2015-08-25 | — | — | US | disclosed |
| EP-2523954-B1 | 1H-[1,2,3]TRIAZOLO[4,5-C]PYRIDINE-4- CARBONITRILE DERIVATIVES AS CATHEPSIN S INHIBITORS | MERCK SHARP & DOHME (NL) | 2014-04-16 | — | — | EP | disclosed |
| EP-2523954-B1 | 1H-[1,2,3]TRIAZOLO[4,5-C]PYRIDINE-4- CARBONITRILE DERIVATIVES AS CATHEPSIN S INHIBITORS | MERCK SHARP & DOHME (NL) | 2014-04-16 | — | — | EP | disclosed |
| EP-2523954-A1 | 1H-[1,2,3]TRIAZOLO[4,5-c]PYRIDINE-4-CARBONITRILE DERIVATIVES | MSD Oss B.V. (NL) | 2012-11-21 | — | — | EP | disclosed |
| US-20120283239-A1 | 1H-[1,2,3]TRIAZOLO[4,5-c]PYRIDINE-4-CARBONITRILE DERIVATIVES | MSD OSS B.V. (NL) | 2012-11-08 | — | — | US | disclosed |
| US-20120283239-A1 | 1H-[1,2,3]TRIAZOLO[4,5-c]PYRIDINE-4-CARBONITRILE DERIVATIVES | MSD OSS B.V. (NL) | 2012-11-08 | — | — | US | disclosed |
| WO-2011086125-A1 | 1H-[1,2,3]TRIAZOLO[4,5-c]PYRIDINE-4-CARBONITRILE DERIVATIVES | N.V. ORGANON (NL) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011086125-A1 | 1H-[1,2,3]TRIAZOLO[4,5-c]PYRIDINE-4-CARBONITRILE DERIVATIVES | N.V. ORGANON (NL) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283239-A1 | 1H-[1,2,3]TRIAZOLO[4,5-c]PYRIDINE-4-CARBONITRILE DERIVATIVES | CTSS, CTSV, CTSZ | CYP3A4 1143/4885CYP1A2 1274/4885GLA 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.